163 related articles for article (PubMed ID: 35385885)
1. Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
Labreuche J; Assouan D; Durot E; Tomowiak C; Roos-Weil D; Toussaint E; Bijou F; Lemal R; Brion A; Laribi K; Ysebaert L; Duhamel A; Morel P;
Hematol Oncol; 2022 Aug; 40(3):400-408. PubMed ID: 35385885
[TBL] [Abstract][Full Text] [Related]
2. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Guidez S; Labreuche J; Drumez E; Ysebaert L; Bakala J; Delette C; Hivert B; Protin C; Declercq H; Verlay M; Marolleau JP; Duhamel A; Morel P;
Blood Adv; 2018 Nov; 2(22):3102-3111. PubMed ID: 30455359
[TBL] [Abstract][Full Text] [Related]
3. Progression in smoldering Waldenstrom macroglobulinemia: long-term results.
Kyle RA; Benson JT; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Melton LJ; Rajkumar SV
Blood; 2012 May; 119(19):4462-6. PubMed ID: 22451426
[TBL] [Abstract][Full Text] [Related]
4. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
[TBL] [Abstract][Full Text] [Related]
5. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
[TBL] [Abstract][Full Text] [Related]
6. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.
Luminari S; Merli M; Rattotti S; Tarantino V; Marcheselli L; Cavallo F; Varettoni M; Bianchi B; Merli F; Tedeschi A; Cabras G; Re F; Visco C; Torresan Delamain M; Cencini E; Spina M; Ferrero S; Ferrari A; Deodato M; Mannina D; Annibali O; Rago A; Orsucci L; Defrancesco I; Frigeni M; Cesaretti M; Arcaini L
Blood; 2019 Sep; 134(10):798-801. PubMed ID: 31292118
[TBL] [Abstract][Full Text] [Related]
7. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
8. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
García-Sanz R; Dogliotti I; Zaccaria GM; Ocio EM; Rubio A; Murillo I; Escalante F; Aguilera C; García-Mateo A; García de Coca A; Hernández R; Dávila J; Puig N; García-Álvarez M; Chillón MDC; Alcoceba M; Medina A; González de la Calle V; Sarasquete ME; González M; Gutiérrez NC; Jiménez C
Br J Haematol; 2021 Mar; 192(5):843-852. PubMed ID: 32780894
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma.
Suzuki Y; Yano T; Suehiro Y; Iwasaki H; Hidaka M; Otsuka M; Sunami K; Ikeda H; Sawamura M; Ito T; Iida H; Nagai H
Int J Hematol; 2020 Dec; 112(6):817-824. PubMed ID: 32886278
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of POD24 in peripheral T-cell lymphoma.
Chen H; Ma R; Zhang Q; Lu F; Ma Y; Zhou J; Cao J; Qi K; Yan Z; Sang W; Zhu F; Sun H; Li D; Li Z; Cheng H; Xu K; Chen W
Hematology; 2024 Dec; 29(1):2304483. PubMed ID: 38251872
[TBL] [Abstract][Full Text] [Related]
11. Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months.
Yoon SE; Cho J; Kim WS; Kim SJ
J Cancer; 2021; 12(9):2488-2497. PubMed ID: 33854610
[No Abstract] [Full Text] [Related]
12. Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.
Bitansky G; Avigdor A; Vasilev E; Zlotnick M; Ribakovsky E; Benjamini O; Nagler A; Kedmi M
Leuk Lymphoma; 2020 Nov; 61(11):2645-2651. PubMed ID: 32643497
[TBL] [Abstract][Full Text] [Related]
13. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.
Riva E; Duarte PJ; Valcárcel B; Remaggi G; Murrieta I; Corzo A; Del Carpio D; Peña C; Vásquez J; Bove V; Teixeira L; Fleury-Perini G; Yantorno S; Samánez C; Lopresti S; Altamirano M; Villela L; Ruiz-Arguelles GJ; Ruiz-Delgado GJ; Montaño E; Verri V; Zamora Pérez E; Pérez Jacobo F; Idrobo H; Martínez-Cordero H; Beltran BE; Ramírez J; Castillo JJ; Malpica Castillo LE
JCO Glob Oncol; 2022 Aug; 8():e2100380. PubMed ID: 35939775
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
Kyle RA; Therneau TM; Dispenzieri A; Kumar S; Benson JT; Larson DR; Melton LJ; Rajkumar SV
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):184-6. PubMed ID: 23490989
[TBL] [Abstract][Full Text] [Related]
15. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.
Gao F; Zhang T; Liu H; Li W; Liu X; Qiu L; Li L; Zhou S; Qian Z; Dong S; Zhao S; Wang X; Zhang H
Ann Hematol; 2022 Nov; 101(11):2383-2392. PubMed ID: 36029326
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Moccia AA; Schär S; Hayoz S; Pirosa MC; Taverna C; Novak U; Kimby E; Ghielmini M; Zucca E
Br J Haematol; 2021 Mar; 192(6):1031-1034. PubMed ID: 32805081
[TBL] [Abstract][Full Text] [Related]
18. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
Epperla N; Welkie RL; Torka P; Shouse G; Karmali R; Shea L; Anampa-Guzmán A; Oh TS; Reaves H; Tavakkoli M; Lindsey K; Greenwell IB; Hansinger E; Thomas C; Chowdhury SM; Annunzio K; Christian B; Barta SK; Geethakumari PR; Bartlett NL; Herrera AF; Grover NS; Olszewski AJ
J Hematol Oncol; 2023 May; 16(1):49. PubMed ID: 37158890
[TBL] [Abstract][Full Text] [Related]
19. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic cell transplantation for Waldenström macroglobulinemia.
Bachanova V; Burns LJ
Bone Marrow Transplant; 2012 Mar; 47(3):330-6. PubMed ID: 21572463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
